Analysts Have Made A Financial Statement On Mankind Pharma Limited’s (NSE:MANKIND) Yearly Report

It’s been a good week for Mankind Pharma Limited (NSE:MANKIND) shareholders, because the company has just released its latest annual results, and the shares gained 2.1% to ₹2,514. The result was positive overall – although revenues of ₹143b were in line with what the analysts predicted, Mankind Pharma surprised by delivering a statutory profit of ₹46.28 per share, modestly greater than expected. Earnings are an important time for investors, as they can track a company’s performance, look at what the analysts are forecasting for next year, and see if there’s been a change in sentiment towards the company. We’ve gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Trump has pledged to “unleash” American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, the current consensus from Mankind Pharma’s 19 analysts is for revenues of ₹160.0b in 2027. This would reflect a notable 12% increase on its revenue over the past 12 months. Per-share earnings are expected to soar 24% to ₹57.42. Before this earnings report, the analysts had been forecasting revenues of ₹159.4b and earnings per share (EPS) of ₹58.42 in 2027. The consensus analysts don’t seem to have seen anything in these results that would have changed their view on the business, given there’s been no major change to their estimates.

View our latest analysis for Mankind Pharma

There were no changes to revenue or earnings estimates or the price target of ₹2,639, suggesting that the company has met expectations in its recent result. That’s not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Mankind Pharma, with the most bullish analyst valuing it at ₹3,100 and the most bearish at ₹1,990 per share. As you can see, analysts are not all in agreement on the stock’s future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Of course, another way to look at these forecasts is to place them into context against the industry itself. It’s pretty clear that there is an expectation that Mankind Pharma’s revenue growth will slow down substantially, with revenues to the end of 2027 expected to display 12% growth on an annualised basis. This is compared to a historical growth rate of 16% over the past five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 12% annually. So it’s pretty clear that, while Mankind Pharma’s revenue growth is expected to slow, it’s expected to grow roughly in line with the industry.

The Bottom Line

The most important thing to take away is that there’s been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company’s earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Mankind Pharma going out to 2029, and you can see them free on our platform here..

It might also be worth considering whether Mankind Pharma’s debt load is appropriate, using our debt analysis tools on the Simply Wall St platform, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.